Yes. Once-daily oral denifanstat 50 mg reduced inflammatory acne lesions by 77% from baseline after up to 52 weeks of total exposure, according to HCPLive reporting on 52-week extension results. Denifanstat is a first-in-class oral fatty-acid synthase inhibitor, a drug that blocks an enzyme involved in making sebum lipids.
The result applies to adults with moderate-to-severe acne vulgaris in a long-term Chinese trial program. It reflects continued treatment, not a short course. The drug is still investigational in the United States.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How does denifanstat target acne?
- Who was included in the 52-week data?
- What improved besides inflammatory lesions?
- What should readers do now?
How does denifanstat target acne?
Denifanstat blocks de novo lipogenesis, the process skin uses to make new fatty acids. Less new fat means less sebum lipid available to clog pores. The drug also targets inflammation tied to acne breakouts.
That approach differs from antibiotics, retinoids, and hormonal treatments. Instead of killing bacteria or increasing cell turnover, it acts earlier in oil production. For readers with oily skin and inflamed papules or pustules, the mechanism is directly relevant.
Who was included in the 52-week data?
The affected population was adults ages 18 to 40 with moderate-to-severe acne vulgaris enrolled in Ascletis trials ASC40-303 and ASC40-304 in China, according to a BioSpace/Ascletis press release on Phase 3 open-label results. Ascletis holds the China license, while Sagimet develops denifanstat elsewhere.
The long-term phase, ASC40-304, was a multicenter open-label extension. Sagimet reported through Seeking Alpha that 240 completers from a 12-week 480-patient randomized trial received denifanstat for up to 40 additional weeks in full 52-week results. That design measures sustained response in people who stayed on treatment.
What improved besides inflammatory lesions?
The same 52-week regimen reduced total lesions by 72% from baseline. It also achieved 57% Investigator's Global Assessment success, a clinician rating of clear or almost clear skin with meaningful improvement.
Together, those outcomes cover inflamed bumps, noninflamed clogged pores, and overall severity. A 77% inflammatory-lesion drop matters most for painful red bumps. Total-lesion and global-success rates show whether the broader complexion also looked better.
What should readers do now?
Denifanstat is investigational in the U.S., so readers cannot request it as a prescription yet. Screening for Sagimet's AURORA Phase 3 trial was expected in October 2026, and China NDA acceptance was reported in December 2025.
Readers who want to follow this option can take practical steps: Through 52 weeks, denifanstat was reported as generally well-tolerated, with no permanent discontinuations tied to adverse events and no reported drug-related grade 3/4 events or serious adverse events. The 52-week efficacy data are uncontrolled open-label findings without a placebo comparison. Talk with a dermatologist before changing treatment while awaiting further trial results.
- Ask a dermatologist whether a future sebum-targeting oral could fit their acne type.
- Keep a short record of inflammatory lesion counts, current treatments, and past isotretinoin or antibiotic use.
- Watch for enrollment notices for moderate-to-severe acne trials if current therapy is inadequate.
- Continue proven care, including gentle cleansing, noncomedogenic moisturizer, and prescribed retinoids or benzoyl peroxide, unless a clinician advises otherwise.